Journal list menu

Graphical Abstract: The 12 randomized controlled phase II/III trials investigating CDK4/6i with endocrine therapy included 17,440 patients with HR+ HER2- breast cancer. The number of patients was 9,255 in the CDK4/6i group and 8185 in the control group. The rate of arthralgia in the CDK4/6i group was significantly lower than that in the control group, in the total population (27.6% vs. 34.8%, p < .001), especially in the EBC setting (28.8% vs. 37.3%, p < .001).

Incidence and mortality rates of breast cancer have been increasing in China, with a relatively low survival rate compared to other developed countries. Urban-rural disparities are present in the incidence, mortality, and survival rates, highlighting the need to ensure adequate distribution of medical resources and equal accessibility to medical care.

Overall survival was prolonged with pembrolizumab plus chemotherapy compared with placebo plus chemotherapy among patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer enrolled in the global, phase 3 randomized controlled trial KEYNOTE-355. In this analysis of outcomes in patients in KEYNOTE-355 who were enrolled in Japan, pembrolizumab plus chemotherapy improved overall survival versus placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer with manageable toxicity.

KLF5 is a key transcription factor in cancers. This article reviews the functions, mechanisms, and regulations of KLF5.

​

Graphical Headlights

• Cancer-associated fibroblasts (CAFs) play a great role in breast cancer progression.
• MicroRNAs (miRNAs) play an important role in the transformation of normal fibroblasts to CAF.
• miRNA-200c overexpression decreases the invasive features of cancer cells.

This commentary frames the novelty of Xiong et al (Clinical and Translational Medicine, 2022) in the context of the field. Research most directly related to DAB2IP's function as a tumor suppressor are briefly summarized and referenced, particularly in reference to breast cancer and the findings by Xiong et al related to RAC1.

DAB2IP attenuates CSC capacity and chemoresistance in TNBC. DAB2IP inhibits β-catenin nuclear transport through competitive binding to RAC1. Hypermethylation at DAB2IP is associated with low DAB2IP expression and poor prognosis in TNBC. Decitabine treatment inhibits DNA methylation at DAB2IP and improves response to chemotherapy in TNBC.

What's new?

Evidence for the long-term outcomes of platinum-based (anthracycline-free) neoadjuvant chemotherapy for triple-negative breast cancer remains scarce. In this prospective study conducted among stage II-III triple-negative breast cancer patients, patients who received neoadjuvant chemotherapy with dose-dense paclitaxel plus carboplatin (ddPCb) had a significantly better recurrence-free survival and overall survival, compared to the matched cohort receiving standard adjuvant chemotherapy. Moreover, ddPCb was related to less neutropenia and more thrombocytopenia. Altogether, the findings support the consideration of platinum-based neoadjuvant chemotherapy for promising survival benefits, and the ddPCb regimen is emerging as an innovative and well-tolerated option.

The aim of this in silico study was to evaluate the dosimetric aspects of 1-week RT course administered with VMAT technique, compared with 3D-CRT tangential field traditional irradiation technique in adjuvant treatment of breast cancer. A total of 21 patients with left-side early breast cancer were selected, and 3D-CRT tangential fields and VMAT plans were generated for each patient. The results showed that both 3D-CRT and VMAT are feasible techniques in terms of dosimetric outcomes.

Accelerated partial breast irradiation (APBI) is the most common form of treatment for MRIgRT. The presence of the magnet does not affect target coverage or violate organ at risk (OAR) constraints compared to standard RT methods. Consideration is advised for skin and chestwall (CW) due to the electron return effect (ERE) and areas such as armpit and chin due to the electron stream effect (ESE).

This study demonstrates the utility of circulating tumor DNA (ctDNA) methylation analysis in early detection and molecular subtyping for breast cancer. The improved ctDNA whole-genome bisulfite sequencing method was effective at developing novel sensitive and specific biomarkers for the diagnosis, early detection, and molecular subtyping of breast cancer. We anticipate that the method and diagnostic biomarkers of breast cancer have substantial clinical translation potential.

Invasive cancer cell growth and metastasis accounts for the poor prognosis of high-grade breast cancer. The transcription factor Yin Yang 1 (YY1) is upregulated in high-grade breast cancer. YY1 interacted with DEAD-box protein (DDX3X) via binding to DDX3X. YY1 transactivated KTN1 gene via direct binding its promoter together with the DDX3X. Herein, our findings established a novel YY1-assisted DDX3X-KTN1 regulatory axis, which would shed some light on the signaling involved in cell invasion and progression in breast cancer and open an avenue in finding novel therapeutic targets for breast cancer.